New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

Please provide your email address to receive an email when new articles are posted on . Beta-blockers more effectively reduce risk for death or hospitalization in people with HFpEF compared with ...

New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

A woman with hopes to conceive was diagnosed with severe vasospastic angina (VSA); however, she was able to carry a healthy baby to full term without angina attacks after starting treatment of a ...

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 23, entitled, “Benidipine calcium channel blocker ...

Myotonic dystrophy is one of the most common forms of muscular dystrophy. It is a genetic condition that causes progressive muscle weakness and wasting. No treatments currently exist that slow the ...

Please provide your email address to receive an email when new articles are posted on . An ongoing study showed improvements in SSc severity, disease-related pain, Raynaud’s symptoms and ...

Calcium channel blocker toxicity represents a significant clinical challenge owing to its multifaceted pathophysiology and potential to precipitate life‐threatening cardiovascular compromise. Overdose ...

NEW YORK, July 31 (Praxis Press) Cardiovascular outcomes have not been compared in hypertensive patients treated with calcium channel blockers and in patients treated with older drugs. Hansson and ...

Patients on calcium channel blockers (CCBs) had a higher likelihood of glaucoma than their counterparts, according to a population-based, cross-sectional study. Examining data on more than 400,000 ...

What is the best approach for a patient with worsening renal insufficiency and intolerance of ACE inhibitors or angiotensin receptor blockers (ARBs)? —Ann Marchetta, MS, ARNP-C, FNP, Waupaca, Wis.

Active ingredient: Clevidipine butyrate emulsion 0.5 mg/mL; solution for IV infusion; contains lipids 0.2 g/mL (soybean oil, egg phospholipids). Indication: To reduce BP when oral therapy is not ...